10774506

=> d his

(FILE 'HOME' ENTERED AT 15:25:20 ON 09 NOV 2004)

FILE 'REGISTRY' ENTERED AT 15:25:32 ON 09 NOV 2004
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 25 S L1 SSS FULL
L4 24 S L3 NOT C24 H25 N O3 S . CL H /MF

FILE 'CAPLUS' ENTERED AT 15:27:23 ON 09 NOV 2004
L5 8 S L4

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

10774506

=> d 1-8 bib abs hitstr

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:42279 CAPLUS
DN 138:106680
TI Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives, particularly ticlopidine and clopidogrel, via novel intermediates
IN Horne, Stephen E.; Weeratunga, Gamini; Comanita, Bogdan M.; Nagireddy, Jaipal Reddy; McConachie, Laura Kaye
PA Brantford Chemicals Inc., Can.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004502	A1	20030116	WO 2002-CA1017	20020705
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1404681	A1	20040407	EP 2002-745008	20020705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	CA 2001-2352520	A	20010706		
	WO 2002-CA1017	W	20020705		

OS CASREACT 138:106680; MARPAT 138:106680
GI



AB A process for the preparation of tetrahydrothieno[3,2-c]pyridine derivs. I and their pharmaceutically acceptable salts is disclosed [wherein: X = H, CO2H, alkoxycarbonyl, aryloxycarbonyl, nitrile, or CONR1R2; R1, R2 = H, alkyl, or part of a heterocycle; Z = H, halo, alkyl, aryl, aryloxy, or alkoxy]. Compds. I include the com. important drugs ticlopidine and clopidogrel, useful as antithrombotics and platelet aggregation inhibitors. The method comprising the steps of: (a) reduction of amino ketones II with suitable reducing agents to obtain amino alcs. III, (b) cyclization of III with formaldehyde (or any chemical equivalent) to obtain

oxazolidines IV, (c) rearrangement of IV to produce the (hydr)oxy-substituted tetrahydrothienopyridines V [Y = OH, alkanoyloxy, aroyloxy, carbamate or carbonate derivs.], and (d) reduction of V to give I. Synthetic examples are given for the preparation of racemic and (S)-isomeric clopidogrel. For instance, reaction of (S)-Me o-chlorophenylglycinate with 2-(bromoacetyl)thiophene in DMF at room temperature gave (S)-II (X = CO2Me, Z = o-Cl) with 95:5 enantiomeric ratio. Reduction of this ketone with NaBH4 in MeOH gave (S,RS)-III as a mixt of diastereomers. This alc. reacted with 37% formalin in EtOH at 40° to give, after evaporation and azeotropic distillation with PhMe, (S,RS)-IV. Rearrangement of the latter using HCl in dry DMF at 0-35° gave (S,RS)-V, which was reduced by SnCl2.2H2O and concentrated HCl in AcOH to give (S)-I (X = CO2Me, Z = o-Cl), i.e. clopidogrel, with a 98:2 enantiomer ratio. Racemic clopidogrel was prepared likewise. The method uses inexpensive reagents and gives good yields. The novel intermediates in the clopidogrel syntheses and their individual enantiomers are claimed per se.

IT **115608-70-3P**, (±)-Methyl α-(7-hydroxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-α-(o-chlorophenyl)acetate
478083-92-0P, Methyl (S)-α-(7-hydroxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-α-(o-chlorophenyl)acetate
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process intermediate; preparation of tetrahydrothienopyridine derivs., particularly ticlopidine and clopidogrel, via novel intermediates)

RN 115608-70-3 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 478083-92-0 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:960676 CAPLUS
DN 138:24949
TI Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives
IN Horne, Stephen E.; Weeratunga, Gamini; Comanita, Bogdan M.; Nagireddy, Jaipal Reddy; McConachie, Laura Kaye
PA Brantford Chemicals Inc., Can.
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6495691	B1	20021217	US 2001-902165	20010711

1 of 9

10774506

PRAI US 2001-902165 20010711
OS CASREACT 138:24949; MARPAT 138:24949
GI



I

AB Tetrahydrothieno[3,2-c]pyridine derivs. I [X = carboxyl, alkoxycarbonyl, aryloxycarbonyl, or carbamoyl; Z = H, halo, alkyl, aryl, aryloxy, or alkoxy] or their pharmaceutically-acceptable salts were prepared from N-[2-(2-thienyl)-2-oxoethyl]-2-phenylglycinate derivs. Thus, treatment of 2-(bromoacetyl)thiophene with Me (o-chlorophenyl)glycinate in toluene-DMF in the presence of K2CO3 afforded Me N-[2-(2-thienyl)-2-oxoethyl]-2-(o-chlorophenyl)glycinate. The latter underwent borohydride reduction of the oxo group, cyclocondensation with formalin, treatment of the 1,3-oxazoline derivative with HCl in dry DMF, and dehydroxylation with HCl and SnCl2 in acetic acid to afford I (X = CO2Me, Z = 2-Cl).

IT **115608-70-3P 478083-92-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (tetrahydrothienopyridyl)(chlorophenyl)acetate)

RN 115608-70-3 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 478083-92-0 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:473415 CAPLUS
DN 109:73415
TI Preparation of 6,7-dihydro-α-phenyl-thieno[3,2-c]pyridine-5(4H)-acetates as antithrombotics
IN Frehel, Daniel; Maffrand, Jean Pierre; Vallee, Eric; Badorc, Alain
PA SANOFI, Fr.
SO Fr. Demande, 17 pp.
CODEN: FRXXBL
DT Patent

10774506

LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2597102	A1	19871016	FR 1986-5818	19860414
	FR 2597102	B1	19880826		
PRAI	FR 1986-5818		19860414		

GI



I

AB The title compds. [I; R = (un)substituted Ph; R1 = R2, R3CO; R2 = H, (un)saturated alkyl, (un)substituted aralkyl; R3 = alkyl, (un)substituted aryl, aralkyl], their stereoisomers and pharmaceutically acceptable salts, were prepared as blood platelet aggregation inhibitors, useful as antithrombotics. 4,5,6,7-Tetrahydrothieno[3,2-c]pyridin-7-ol-HCl and 2-ClC6H4CHClCO2Me were heated 3 h at 70° in DMF containing K2CO3 to give I (R = 2-ClC6H4, R1 = H, R2 = Me) (II), as a mixture of 2 diastereomers. Blood plasma from rats receiving 200 mg II/kg/day orally for 3 days had a 51% reduction in collagen-induced platelet aggregation, compared to 32% for ticlopidine.

IT **115608-70-3P 115608-71-4P 115608-72-5P**
115608-73-6P 115608-74-7P 115608-75-8P
115608-78-1P 115608-79-2P 115608-86-1P
115608-87-2P 115608-88-3P 115653-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antithrombotic)

RN 115608-70-3 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 115608-71-4 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-72-5 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester, (R*,S*)- (9CI) (CA INDEX NAME)

10774506

Relative stereochemistry.



RN 115608-73-6 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester, hydrochloride, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 115608-74-7 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, ethyl ester, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-75-8 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, ethyl ester, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-78-1 CAPLUS

CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, 1,1-dimethylethyl ester, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-79-2 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, 1,1-dimethylethyl ester, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-86-1 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-87-2 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 115608-88-3 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 115653-25-3 CAPLUS
CN Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-7-hydroxy-, methyl ester, hydrochloride, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1980:215425 CAPLUS
DN 92:215425
TI Thieno[2,3-c]- and thieno[3,2-c]pyridines
IN Boigegrain, Robert; Maffrand, Jean Pierre
PA Parcor, Fr.
SO Fr. Demande, 10 pp.
CODEN: FRXXBL
DT Patent
LA French

1449.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2424278	A1	19791123	FR 1978-12037	19780424
	FR 2424278	B1	19801024		
PRAI	FR 1978-12037		19780424		

GI



AB Tetrahydrothienopyridines I [R = H, halo, alkyl; R1 = alkyl, aralkyl, (halophenyl)-, (alkylphenyl)-, or (alkoxyphenyl)alkyl] were converted to the resp. thieno[3,2-c]pyridines II; similarly prepared were thieno[2,3-c]pyridines III. Thus, I (R = Me, R1 = 2-ClC6H4CH2) was stirred with N-bromosuccinimide in CHCl3, the solvent was removed, the residue was dissolved in DMF, 1,4-diazabicyclo[2.2.2]octane was added, and the mixture was heated 3 h at 120° to give II (R = Me).

IT **61923-09-9P 73099-80-6P 73099-81-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and aromatization of)

RN 61923-09-9 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 73099-80-6 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 73099-81-7 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 2-chloro-5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



IT **61962-12-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, and aromatization of base from)

RN 61962-12-7 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1980:128769 CAPLUS
DN 92:128769
TI New synthesis of thieno[3,2-c]pyridines
AU Maffrand, Jean Pierre; Biogegrain, Robert
CS Dep. Rech. Dev., PARCOR, Toulouse, 31024, Fr.
SO Heterocycles (1979), 12(11), 1479-82
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 92:128769

1449

10774506

GI



AB Thiophenecarboxaldehydes I (R = H, Me, Cl; R1 = CHO) were treated with Me(CH2)11S+Me2 MeOSO3- in C6H6 containing 50% NaOH to give I (R1 = oxiranyl), which were treated with 2-ClC6H4CH2NH2 to give 55-69% (aminoethyl)thiophenes II. Cyclocondensation of II with HCHO gave oxazolidines III, the hydrochlorides of which rearranged in refluxing PhMe to give thienopyridines IV. Oxidation of IV by bromosuccinimide and subsequent treatment with diazabicyclooctane in DMF at 120° gave thienopyridines V.

IT **61923-09-9P 73099-80-6P 73099-81-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

RN 61923-09-9 CAPLUS

CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 73099-80-6 CAPLUS

CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)



RN 73099-81-7 CAPLUS

CN Thieno[3,2-c]pyridin-7-ol, 2-chloro-5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)

10774506



L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1978:597516 CAPLUS
DN 89:197516
TI 4,5,6,7-Tetrahydrothieno[2,3-c] and [3,2-c]pyridines
IN Maffrand, Jean Pierre
PA Parcor, Fr.
SO Ger. Offen., 31 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2800596	A1	19780713	DE 1978-2800596	19780107
	DE 2800596	C2	19851212		
	FR 2376860	A1	19780804	FR 1977-408	19770107
	FR 2376860	B1	19790420		
	US 4147787	A	19790403	US 1977-864939	19771227
	IL 53708	A1	19800916	IL 1977-53708	19771228
	SE 7714940	A	19780708	SE 1977-14940	19771230
	SE 421922	B	19820208		
	SE 421922	C	19820527		
	NL 7800034	A	19780711	NL 1978-34	19780102
	NL 184220	B	19881216		
	NL 184220	C	19890516		
	GB 1574394	A	19800903	GB 1978-68	19780103
	HU 175645	P	19800928	HU 1978-PA1299	19780103
	ZA 7800033	A	19781129	ZA 1978-33	19780104
	AT 7800061	A	19791215	AT 1978-61	19780104
	AT 357532	B	19800710		
	CA 1087187	A1	19801007	CA 1978-294348	19780104
	CH 631179	A	19820730	CH 1978-71	19780104
	ES 465683	A1	19781001	ES 1978-465683	19780105
	DD 133673	C	19790117	DD 1978-203109	19780105
	BE 862695	A1	19780706	BE 1978-184146	19780106
	FI 7800048	A	19780708	FI 1978-48	19780106
	FI 62308	B	19820831		
	FI 62308	C	19821210		
	DK 7800075	A	19780708	DK 1978-75	19780106
	DK 147826	B	19841217		
	DK 147826	C	19850610		
	NO 7800050	A	19780710	NO 1978-50	19780106
	AU 7832238	A1	19790712	AU 1978-32238	19780106
	AU 508277	B2	19800313		
	SU 683625	D	19790830	SU 1978-2562904	19780106
	PL 118048	B1	19810930	PL 1978-203863	19780106
	JP 53087394	A2	19780801	JP 1978-787	19780107
	JP 60040436	B4	19850911		
PRAI	FR 1977-408		19770107		

GI



I



II

AB The title compds. I and II [R = R3 = H, C1-6 alkyl, (substituted) phenylalkyl; R1 = H, halogen; R2 = H, OH] and their salts were prepared for use as antithrombics (test data tabulated). Thus, β-(2-thienyl)serine was condensed with 35% aqueous HCHO in the presence of H2SO4 to give II (R = R1 = R3 = H, R2 = OH).

IT **68056-10-0P**

10774506

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antithrombic activity of)
RN 68056-10-0 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxylic acid, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-7-hydroxy-, (2-chlorophenyl)methyl ester, hydrochloride (9CI) (CA INDEX NAME)





● HCl

IT **68056-09-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 68056-09-7 CAPLUS
CN Thieno[3,2-c]pyridine-6-carboxylic acid, 4,5,6,7-tetrahydro-7-hydroxy-5-(phenylmethyl)-, phenylmethyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:106435 CAPLUS
DN 86:106435
TI New syntheses of thieno[3,2-c]- and thieno[2,3-c]pyridines
AU Maffrand, J. P.; Eloy, F.
CS Dep. Rech. Dev., PARCOR, Toulouse, Fr.
SO Journal of Heterocyclic Chemistry (1976), 13(6), 1347-9
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA French
OS CASREACT 86:106435
GI



AB A new method for the synthesis of thieno[2,3-c]- and [3,2-c]-pyridines I and II (R = H, CH2C6H4Cl-2; Z = O; H,OH) and of their tetrahydro derivs. is described. The process is based on a modified Pomeranz-Fritsch

reaction, leading to isoquinolines.

IT **61923-09-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)

RN 61923-09-9 CAPLUS

CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1977:89789 CAPLUS

DN 86:89789

TI Thienopyridine derivatives

IN Maffrand, Jean P.

PA Parcor, Fr.

SO Ger. Offen., 21 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2623567	A1	19761209	DE 1976-2623567	19760526
	DE 2623567	C2	19840301		
	FR 2312247	A1	19761224	FR 1975-17007	19750530
	CH 613969	A	19791031	CH 1976-3456	19760319
	IL 49405	A1	19790930	IL 1976-49405	19760413
	ZA 7602263	A	19770427	ZA 1976-2263	19760414
	CA 1071633	A1	19800212	CA 1976-250739	19760414
	ES 447570	A1	19770701	ES 1976-447570	19760504
	NL 7604944	A	19761202	NL 1976-4944	19760507
	SU 667138	D	19790605	SU 1976-2356004	19760517
	RO 68891	P	19820909	RO 1976-86177	19760522
	AT 349471	B	19790410	AT 1976-3865	19760526
	BE 842310	A1	19761129	BE 1976-167404	19760528
	DK 7602358	A	19761201	DK 1976-2358	19760528
	DD 125214	C	19770406	DD 1976-193073	19760528
	GB 1501797	A	19780222	GB 1976-22400	19760528
	AU 498517	B2	19790315	AU 1976-14417	19760528
	SE 421623	B	19820118	SE 1976-6062	19760528
	SE 421623	C	19820429		
	JP 51149297	A2	19761222	JP 1976-62884	19760529
	PL 100792	P	19781130	PL 1976-189958	19760529
PRAI	FR 1975-17007		19750530		

GI



AB Tetrahydrothienopyridines I (R = e.g. pyrrolidinoacetyl, 4-ClC6H4CO, 4-MeC6H4SO2, PhNHCO; R1 = e.g. H, PrNHCO, Ac, MeNHCO, EtNHCO) II (R = e.g. 4-O2NC6H4CH2, MeCOCH2CH2, 2-ClC6H4CH2, Me; R1 = H, Ac), useful as inflammation inhibitors and blood platelet aggregation inhibitors, are prepared by standard procedures. Thus, reaction of II (R = R1 = H) with 4-O2NC6H4CH2Cl in refluxing EtOH in presence of K2CO3 gives after 1.5 h 52% II.HCl (R = 4-O2NC6H4CH2, R1 = H).

IT **61923-09-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(acetylation of)

10774506

RN 61923-09-9 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



IT **61922-75-6P 61923-07-7P 61962-12-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, antiinflammatory and antithrombic activity of)
RN 61922-75-6 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 4,5,6,7-tetrahydro-5-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 61923-07-7 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 4,5,6,7-tetrahydro-5-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 61962-12-7 CAPLUS
CN Thieno[3,2-c]pyridin-7-ol, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1022	iodotrimethylsilane	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 14:51
L2	1049	tmsi	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 14:51
L3	85	iodosilane or iodosilanes	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 14:52
L4	2044	l1 or l2 or l3	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 14:52
L5	800	dehydroxylation	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 14:53
L6	6	l4 and l5	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:00
L7	164	SnCl2	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:01
L8	0	l4 and l7	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:01
L9	72	iodotrimethylsilane or tmsi	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:02
L10	12	iodosilane or iodosilanes	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:02
L11	84	l9 or l10	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:02
L12	1380	sncl2	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:03
L13	0	l11 and l12	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:03
L14	89	dehydroxylation	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:03
L15	0	l11 and l14	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:03
L16	0	l12 and l14	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:04
L17	71	clopidogrel	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:04
L18	0	l11 and l17	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:05

L19	0	l12 and l17	EPO; JPO; DERWENT	OR	OFF	2004/11/09 15:05
L20	687	clopidogrel	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:05
L21	25	l4 and l20	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:16
L22	164	sncl2	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:16
L23	0	l4 and l22	US-PGPUB; USPAT; USOCR	OR	OFF	2004/11/09 15:16